EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Open Access

Evaluation of the drug interaction between rifabutin and elexacaftor/tezacaftor/ivacaftor (ETI)

Madeline Sanders, Eunjin Hong, Peter S Chung, Adupa P Rao, Whitaker Cohn, Paul Beringer

Journal of Cystic Fibrosis · 2026

DOI: 10.1016/j.jcf.2025.09.002 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Journal of Cystic Fibrosis, 2026. Verfasst von Madeline Sanders und 5 weiteren Autor:innen. Beteiligte Einrichtung: Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Aminophenols, Benzodioxoles, Cytochrome P-450 CYP3A Inducers, Indoles. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCR NIH HHS, National Institute of Dental and Craniofacial Research, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Rifampin is a guideline-recommended treatment for nontuberculous mycobacteria infections; however, it is a strong inducer of CYP3A metabolism and therefore is contraindicated in patients receiving elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA; ETI). Rifabutin (RFB), a moderate CYP3A inducer, is a potential therapeutic alternative to rifampin. A prospective, single-arm study was conducted in healthy volunteers to evaluate the effect of RFB on ETI pharmacokinetics (PK) (NCT04840862, 2022-05-09). METHODS: Six adults received a single dose of ETI (100 mg/50 mg/75 mg). After a washout, subjects received 2 weeks of RFB 300 mg daily followed by a second single ETI dose. The data were analyzed using noncompartmental PK. RESULTS: The maximum plasma concentration (Cmax) and area under the curve (AUC0-∞) values following ETI alone were consistent with published data. Both Cmax and AUC0-∞ values were significantly reduced with concomitant RFB as expected. The AUC0-∞ geometric mean ratios (GMR, 90% CI) with RFB vs. alone were: ELX (0.45, 0.35-0.58), TEZ (0.68, 0.56-0.82), and IVA (0.60, 0.45-0.78). Importantly, the AUC0-∞ GMR for IVA with RFB is significantly higher than published data with rifampin. While these data suggest ETI dose adjustment may be needed, population compartmental modeling using standard ETI dosing indicates plasma concentrations remain above half-maximal effective concentration (EC50) values, supporting maintained efficacy. RFB significantly altered IVA metabolite-to-parent ratios, but the reduced activity of M1-IVA suggests limited clinical significance. CONCLUSIONS: RFB alters ETI PK, but to a lesser extent than rifampin. These data indicate that a clinical trial evaluating the efficacy and safety of ETI with concomitant rifabutin treatment is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminophenolsBenzodioxolesCytochrome P-450 CYP3A InducersIndolesPyridinesPyrrolesQuinolonesRifabutinAdultFemaleHumansMaleMiddle AgedYoung AdultDrug CombinationsDrug InteractionsHealthy VolunteersProspective StudiesRifampinPyrazolesPyrrolidines

Stichwörter der Autor:innen

CYP3A4 inductionCystic fibrosisDrug-drug interactionsETIPharmacokineticsRifabutin

Substanzen

AminophenolsBenzodioxolesCytochrome P-450 CYP3A InducersDrug CombinationselexacaftorIndolesPyridinesPyrrolesQuinolonesRifabutin

Autor:innen und Institutionen

  • Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA.
  • College of Pharmacy, Dongguk University, Seoul, South Korea.
  • Division of Pulmonary and Clinical Care Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Anton Yelchin CF Clinic, University of Southern California, Los Angeles, CA, USA.
  • Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA; Anton Yelchin CF Clinic, University of Southern California, Los Angeles, CA, USA. Electronic addres…

Förderung

  • NIDCR NIH HHS
  • National Institute of Dental and Craniofacial Research
  • National Institutes of Health
  • Cystic Fibrosis Foundation

Zitieren

APA

Sanders, M., Hong, E., Chung, P. S., Rao, A. P., Cohn, W., & Beringer, P. (2026). Evaluation of the drug interaction between rifabutin and elexacaftor/tezacaftor/ivacaftor (ETI). Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.09.002

Vancouver

Sanders M, Hong E, Chung PS, Rao AP, Cohn W, Beringer P. Evaluation of the drug interaction between rifabutin and elexacaftor/tezacaftor/ivacaftor (ETI). Journal of Cystic Fibrosis. 2026. doi:10.1016/j.jcf.2025.09.002

BibTeX
@article{Sanders2026,
  author = {Sanders, Madeline and Hong, Eunjin and Chung, Peter S and Rao, Adupa P and Cohn, Whitaker and Beringer, Paul},
  title = {Evaluation of the drug interaction between rifabutin and elexacaftor/tezacaftor/ivacaftor (ETI)},
  journal = {Journal of Cystic Fibrosis},
  year = {2026},
  doi = {10.1016/j.jcf.2025.09.002}
}
Kostenlos starten →